24195-03-7

Basic information

• Product Name: 2,4-PYRIDINECARBOXYLIC ACID, 4-METHYL ESTER
• Synonyms: 2,4-PYRIDINECARBOXYLIC ACID, 4-METHYL ESTER;Pyridine-2,4-dicarboxylic acid 4-methyl ester;2,4-Pyridinedicarboxylicacid, 4-Methyl ester;4-(Methoxycarbonyl)pyridine-2-carboxylic acid;4-(Methoxycarbonyl)picolinic acid;pyridine-2,4-dicarboxylic acid 4-Methyl este;2,4-Pyridinedicarboxylic acid 4-Methyl Ester Pyridine-2,4-Dicarboxylic Acid 4-Methyl Ester
• CAS NO: 24195-03-7
• Molecular Formula: C₈H₇NO₄
• Molecular Weight: 181.15
• EINECS: 200-258-5
• Mol File: 24195-03-7.mol
• Article Data: 6

Chemical Properties

• Melting Point: 153-154 °C
• Boiling Point: 366.8 °C at 760 mmHg
• Flash Point: 175.6 °C
• Appearance: /
• Density: 1.361 g/cm³
• Vapor Pressure: 5.03E-06mmHg at 25°C
• Refractive Index: 1.56
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 3.27±0.10(Predicted)
• CAS DataBase Reference: 2,4-PYRIDINECARBOXYLIC ACID, 4-METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-PYRIDINECARBOXYLIC ACID, 4-METHYL ESTER(24195-03-7)
• EPA Substance Registry System: 2,4-PYRIDINECARBOXYLIC ACID, 4-METHYL ESTER(24195-03-7)

Safety Data

• Hazardous Substances Data: 24195-03-7(Hazardous Substances Data)

Usage

General Description

2,4-Pyridinecarboxylic acid, 4-methyl ester, also known as 4-Picolinic acid methyl ester, is a chemical compound with the formula C7H7NO2. It is a derivative of pyridinecarboxylic acid, which is found in certain plants and is also used in the synthesis of pharmaceuticals and other organic compounds. The 4-methyl ester form of 2,4-pyridinecarboxylic acid is a colorless to slightly yellow liquid with a faint, pleasant odor. It is primarily used as an intermediate in the production of various chemicals and pharmaceuticals, and is also used in the manufacture of insecticides and herbicides. Additionally, it is used as a solvent and as a flavoring agent in the food and beverage industry.

InChI:InChI=1/C8H7NO4/c1-13-8(12)5-2-3-9-6(4-5)7(10)11/h2-4H,1H3,(H,10,11)

Upstream product

• 499-80-9 pyridine-2,4-dicarboxylic acid 
• 25658-36-0 pyridine-2,4-dicarboxylic acid dimethyl ester 

Downstream Products

• 153559-43-4 methyl 2-(chlorocarbonyl)isonicotinate 

Relevant articles and documents

Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy

Histone lysine demethylases (KDMs) have drawn much attention as targets of therapeutic agents. KDM5 proteins, which are Fe(II)/α-ketoglutarate-dependent demethylases, are associated with oncogenesis and drug resistance in cancer cells, and KDM5-selective inhibitors are expected to be anticancer drugs. However, few cell-active KDM5 inhibitors have been reported and there is an obvious need to discover more. In this study, we pursued the identification of highly potent and cell-active KDM5-selective inhibitors. Based on the reported KDM5 inhibitors, we designed several compounds by strategically merging two fragments for competitive inhibition with α-ketoglutarate and for KDM5-selective inhibition. Among them, compounds 10 and 13, which have a 3-cyano pyrazolo[1,5-a]pyrimidin-7-one scaffold, exhibited strong KDM5-inhibitory activity and significant KDM5 selectivity. In cellular assays using human lung cancer cell line A549, 10 and 13 increased the levels of trimethylated lysine 4 on histone H3, which is a specific substrate of KDM5s, and induced growth inhibition of A549 cells. These results should provide a basis for the development of cell-active KDM5 inhibitors to highlight the validity of our inhibitor-based fragment merging strategy.

N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions there-of; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl- CoA carboxylase enzyme(s) in an animal

SUBSTITUTED 3-AMINOQUINUCLIDINES

Compounds of the formula STR1 wherein W, Ar 1, Ar 2 and Ar. sup.3 are defined as below; and the pharmaceutically acceptable salts of such compounds.These compounds are substance P antagonists and useful in the treatment of gastrointestinal disorders, inflammatory disorders, central nervous system disorders and pain.